3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
31
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia, Myeloid, Chronic-Phase
17
Leukemia
12
Breast Neoplasms
12
Prostatic Neoplasms
10
Neoplasm Metastasis
8
Recurrence
6
Pancreatic Neoplasms
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Carcinoma, Non-Small-Cell Lung
6
Melanoma
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Philadelphia Chromosome
4
Multiple Myeloma
4
Lymphoma
4
Burkitt Lymphoma
4
Blast Crisis
4
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Ovarian Neoplasms
3
Glioma
3
Colonic Neoplasms
3
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Polycythemia Vera
2
Neuroblastoma
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
Cyclophosphamide
34
Etoposide
25
Doxorubicin
20
Carboplatin
20
Vincristine
19
Isotretinoin
19
Topotecan
17
Temozolomide
17
Irinotecan
16
Filgrastim
16
Melphalan
15
Cisplatin
15
sargramostim
14
Radiotherapy
14
Granulocyte-Macrophage Colony-Stimulating Factor
13
3-Iodobenzylguanidine
12
dinutuximab
11
Peripheral Blood Stem Cell Transplantation
11
naxitamab
9
Thiotepa
9
Magnetic Resonance Spectroscopy
9
humanized 3F8 anti-GD2 monoclonal antibody
7
Granulocyte Colony-Stimulating Factor
7
Busulfan
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Ifosfamide
6
Antilymphocyte Serum
6
fludarabine phosphate
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroblastoma
×
Dasatinib
×
Clear all
NCT02559778
2026-04-28
PEDS-PLAN
Milton S. Hershey Medical Center
Phase 2
Recruiting
500 enrolled
NCT01467986
2020-10-06
RIST-rNB-2011
University of Regensburg
Phase 2
Completed
130 enrolled